The good, the bad and the COVID: BioCentury’s playlist for pandemic times
BioCentury’s editorial team picks biopharma’s best and worst in a difficult year and looks ahead to a brighter New Year
BioCentury’s editorial team make their picks for the best and worst in biopharma this year and offer their predictions for a brighter 2021.
Saying goodbye to a grueling year, BioCentury editors have furrowed among the disasters to pick out some of the positives from 2020, and call out some of the worst of the pandemic’s collateral damage. Then they put their goggles on for where the sun might shine in 2021.
Best of 2020
Simone Fishburn, Editor in Chief
Master protocols proved their worth and diagnostics finally got some respect, with PCR and antigen testing becoming household terms. Data-sharing inched forward, and the biopharma industry showed the world the value of its day